Irbesartan Basi (Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors, preventing angiotensin II from causing blood vessels to narrow and from stimulating aldosterone release. This results in vasodilation, reduced fluid retention, and lower systemic blood pressure, while also limiting harmful cardiac and renal remodeling.

The exact dose of Irbesartan Basi is determined by the prescribing clinician based on the individual’s blood pressure, kidney function, and other medical factors. The prescriber will select an appropriate strength and dosing schedule that best fits the patient’s therapeutic needs.

Irbesartan is contraindicated in pregnancy because it can cause fetal toxicity, including renal failure and death. Limited data are available for breastfeeding; therefore, the drug is generally not recommended for nursing mothers unless the potential benefit justifies the potential risk.

To order Irbesartan Basi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, which offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers or diuretics, ARBs provide additional renal protection in diabetic patients and are often combined with those agents for synergistic effect.

Irbesartan Basi tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Irbesartan Basi is taken orally, usually once daily. The tablet should be swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious adverse events include hyperkalaemia (elevated potassium levels), acute kidney injury, severe hypotension, and angioedema. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, or a marked decrease in urine output.

Irbesartan Basi should not be used by individuals who are pregnant, have known hypersensitivity to Irbesartan or any ARB, or have severe hepatic impairment. Caution is also advised for patients with existing renal dysfunction, high potassium levels, or those taking interacting medications.